Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI

NCT00517192 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Tipranavir
DRUG: Darunavir
DRUG: Ritonavir

Sponsor

Boehringer Ingelheim